27312152|t|Association of Low Ficolin - Lectin Pathway Parameters with Cardiac Syndrome X
27312152|a|In patients with typical angina pectoris, inducible myocardial ischaemia and macroscopically normal coronaries (cardiac syndrome X (CSX)), a significantly elevated plasma level of terminal complement complex (TCC), the common end product of complement activation, has been observed without accompanying activation of the classical or the alternative pathways. Therefore, our aim was to clarify the role of the ficolin - lectin pathway in CSX. Eighteen patients with CSX, 37 stable angina patients with significant coronary stenosis (CHD) and 54 healthy volunteers (HC) were enrolled. Serum levels of ficolin-2 and ficolin-3, ficolin-3 / MASP-2 complex and ficolin-3 -mediated TCC deposition (FCN3 - TCC) were determined. Plasma level of TCC was significantly higher in the CSX than in the HC or CHD group (5.45 versus 1.30 versus 2.04 AU/ml, P < 0.001). Serum levels of ficolin-2 and ficolin-3 were significantly lower in the CSX compared to the HC or CHD group (3.60 versus 5.80 or 5.20 μg/ml, P < 0.05; 17.80 versus 24.10 or 26.80 μg/ml, P < 0.05). The ficolin-3 / MASP-2 complex was significantly lower in the CSX group compared to the HC group (92.90 versus 144.90 AU/ml, P = 0.006). FCN3 - TCC deposition was significantly lower in the CSX group compared to the HC and CHD groups (67.8% versus 143.3% or 159.7%, P < 0.05). In the CSX group, a significant correlation was found between TCC and FCN3 - TCC level (r = 0.507, P = 0.032) and between ficolin-3 / MASP-2 complex level and FCN3 - TCC deposition (r = 0.651, P = 0.003). In conclusion, in patients with typical angina and myocardial ischaemia despite macroscopically normal coronary arteries, low levels of several lectin pathway parameters were observed, indicating complement activation and consumption. Complement activation through the ficolin - lectin pathway might play a role in the complex pathomechanism of CSX.
27312152	19	26	Ficolin	T103	UMLS:C0217532
27312152	29	35	Lectin	T103	UMLS:C0023206
27312152	36	43	Pathway	T038	UMLS:C0312755
27312152	60	78	Cardiac Syndrome X	T038	UMLS:C0206064
27312152	96	119	typical angina pectoris	T033	UMLS:C0002962
27312152	131	151	myocardial ischaemia	T038	UMLS:C0151744
27312152	179	189	coronaries	T017	UMLS:C0018787
27312152	191	209	cardiac syndrome X	T038	UMLS:C0206064
27312152	211	214	CSX	T038	UMLS:C0206064
27312152	243	249	plasma	T031	UMLS:C0032105
27312152	259	286	terminal complement complex	T103	UMLS:C0009545
27312152	288	291	TCC	T103	UMLS:C0009545
27312152	320	341	complement activation	T038	UMLS:C0009528
27312152	400	409	classical	T038	UMLS:C0009547
27312152	417	437	alternative pathways	T038	UMLS:C0009546
27312152	489	496	ficolin	T103	UMLS:C0217532
27312152	499	505	lectin	T103	UMLS:C0023206
27312152	506	513	pathway	T038	UMLS:C0312755
27312152	517	520	CSX	T038	UMLS:C0206064
27312152	545	548	CSX	T038	UMLS:C0206064
27312152	560	566	angina	T033	UMLS:C0002962
27312152	593	610	coronary stenosis	T038	UMLS:C0242231
27312152	612	615	CHD	T038	UMLS:C0242231
27312152	624	642	healthy volunteers	T098	UMLS:C1708335
27312152	644	646	HC	T098	UMLS:C1708335
27312152	653	661	enrolled	T062	UMLS:C4041024
27312152	663	668	Serum	T031	UMLS:C0229671
27312152	679	688	ficolin-2	T103	UMLS:C0753749
27312152	693	702	ficolin-3	T103	UMLS:C1431109
27312152	704	713	ficolin-3	T103	UMLS:C1431109
27312152	716	722	MASP-2	T103	UMLS:C0537643
27312152	723	730	complex	T103	UMLS:C1180347
27312152	735	744	ficolin-3	T103	UMLS:C1431109
27312152	755	758	TCC	T103	UMLS:C0009545
27312152	771	775	FCN3	T103	UMLS:C1431109
27312152	778	781	TCC	T103	UMLS:C0009545
27312152	800	806	Plasma	T031	UMLS:C0032105
27312152	816	819	TCC	T103	UMLS:C0009545
27312152	868	870	HC	T098	UMLS:C1708335
27312152	933	938	Serum	T031	UMLS:C0229671
27312152	949	958	ficolin-2	T103	UMLS:C0753749
27312152	963	972	ficolin-3	T103	UMLS:C1431109
27312152	1025	1027	HC	T098	UMLS:C1708335
27312152	1134	1143	ficolin-3	T103	UMLS:C1431109
27312152	1146	1152	MASP-2	T103	UMLS:C0537643
27312152	1153	1160	complex	T103	UMLS:C1180347
27312152	1192	1195	CSX	T038	UMLS:C0206064
27312152	1218	1226	HC group	T098	UMLS:C1708335
27312152	1267	1271	FCN3	T103	UMLS:C1431109
27312152	1274	1277	TCC	T103	UMLS:C0009545
27312152	1320	1323	CSX	T038	UMLS:C0206064
27312152	1346	1348	HC	T098	UMLS:C1708335
27312152	1414	1417	CSX	T038	UMLS:C0206064
27312152	1469	1472	TCC	T103	UMLS:C0009545
27312152	1477	1481	FCN3	T103	UMLS:C1431109
27312152	1484	1487	TCC	T103	UMLS:C0009545
27312152	1529	1538	ficolin-3	T103	UMLS:C1431109
27312152	1541	1547	MASP-2	T103	UMLS:C0537643
27312152	1548	1555	complex	T103	UMLS:C1180347
27312152	1566	1570	FCN3	T103	UMLS:C1431109
27312152	1573	1576	TCC	T103	UMLS:C0009545
27312152	1644	1658	typical angina	T033	UMLS:C1998435
27312152	1663	1683	myocardial ischaemia	T038	UMLS:C0151744
27312152	1708	1732	normal coronary arteries	T033	UMLS:C1299335
27312152	1756	1762	lectin	T103	UMLS:C0023206
27312152	1763	1770	pathway	T038	UMLS:C0312755
27312152	1808	1829	complement activation	T038	UMLS:C0009528
27312152	1834	1845	consumption	T038	UMLS:C1947907
27312152	1847	1868	Complement activation	T038	UMLS:C0009528
27312152	1881	1888	ficolin	T103	UMLS:C0217532
27312152	1891	1897	lectin	T103	UMLS:C0023206
27312152	1898	1905	pathway	T038	UMLS:C0312755
27312152	1957	1960	CSX	T038	UMLS:C0206064